Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myozyme Extensive Phase IV Program Includes Trial In Late-Onset Pompe

Executive Summary

Genzyme's Phase IV commitments for the Pompe disease therapy Myozyme (alglucosidase alfa) include randomized trials in late-onset Pompe disease patients

You may also be interested in...



Therapeutic Biologics Approvals Up In 2006, Overall BLA Approvals Steady

Overall 2006 biological license application approvals held steady from 2005 at 10 approvals, but the year saw a significant increase in approvals of therapeutic biologics

Therapeutic Biologics Approvals Up In 2006, Overall BLA Approvals Steady

Overall 2006 biological license application approvals held steady from 2005 at 10 approvals, but the year saw a significant increase in approvals of therapeutic biologics

Hectorol Will Drive Genzyme’s Renal Business; “Share Of Voice” To Jump

Genzyme expects its acquisition of Bone Care International will drive sales of both Hectorol (doxercalciferol) and Renagel (sevelamer) through the strength of joint promotions

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel